<Anchor>



There are many things to worry about and worry about because of the corona, but there is also good news.

The first vaccine we made with our technology was approved for use late last month, and it has been shown to be effective against omicron mutations.



This information will be delivered by Yoo Seung-hyeon, medical reporter.



<Reporter>



This is Korea's first COVID-19 vaccine, 'Skycobi One Multi-Ju', created with our technology.



SK Bioscience researchers worked day and night to develop it, so it was approved in Korea two years and four months after the start of the development.



Mass production is also possible through automated facilities.



Korea also has the 'vaccine sovereignty' that can secure vaccines stably without relying on imports.



To see the effectiveness and safety, we conducted a phase 3 clinical trial comparing the AstraZeneca vaccine to 4,000 adults over the age of 18.



Two doses of the vaccine, 4 weeks apart, produced about 3 times more neutralizing antibodies than the AstraZeneca vaccine.



It's like Pfizer, Moderna, or Vaccine.



A cellular immune response of lesser severity was also found to be higher than that of the AstraZeneca vaccine.



In March, the government signed a pre-purchase contract for 10 million servings.



The developer said it will be commercialized within this year if it receives national shipment approval.



But there are also challenges.



This is because at present, only the first and second vaccinations are permitted in Korea.



[Ahn Jae-yong/President of SK Bioscience: We need to get WHO permission quickly.

It is basic to get European and UK approval.]



To see the effect of the 3rd dose, 81 adults were vaccinated with Booster Shot 7 months later, and the neutralizing antibody to Omicron was 25 times higher than immediately after the 2nd dose. .



However, it is unclear how effective it will be on BA.5, which has recently become the dominant species.



The developer said that additional clinical trials for the mutation are in progress as well as cross-inoculation trials.



He also announced that he is planning to develop a general-purpose vaccine that is effective against multiple mutations in the long term as well as clinical trials for children and adolescents.



(Video coverage: Jeon Gyeong-bae, video editing: Jo Moo-hwan, CG: Kim Hong-shik·Jo Su-in)



▶ BA.2.75 graded up as 'quasi-worried mutation'...

Korea's first vaccine project